Navigation Links
Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences

Caliper Life Sciences, Inc. (Nasdaq: CALP) and Affymetrix, Inc. (Nasdaq: AFFX) today announced that Caliper has issued Affymetrix a non-exclusive license to use a portion of Caliper's microfluidics patent estate with Affymetrix' GeneChip(R) microarray technologies. The license extends to the manufacture and sale of GeneChip brand products in all areas of application, including research, diagnostics and applied genomics applications. In exchange for the license, Affymetrix will pay upfront licensing fees and royalties on future products covered under the agreement. Further financial details related to the agreement were not disclosed.

The agreement announced today is the second agreement since Caliper began an active program to out-license its intellectual property portfolio. The new "LabChip Driven" program was put in place to support the company's microfluidics adoption strategy and to broaden and accelerate the availability of new technologies and products for life science and diagnostics applications.

"The potential for merging two technologies on the forefront of life science innovation represents an important option for us," said Alan Sherr, Director of Licensing for Affymetrix. "We have worked successfully with Caliper as a partner for a year now, and are pleased to be able to extend the scope of our relationship with Caliper to this new area of potential value and importance to Affymetrix' customers."

"We are pleased that a leading life sciences company like Affymetrix recognizes the vast potential of LabChip technologies," said Kevin Hrusovsky, President and CEO at Caliper. "Affymetrix is moving beyond basic research applications and is pioneering areas such as pharmacogenomics and personalized medicine. Incorporating our technologies -- first laboratory automation and now the potential for Caliper's microfluidics technologies -- into these vital areas of human health is important to our corporate ideals and to our future as a key tech nology provider to the industry."

The scope of the license agreement includes nucleic acids processing and handling associated with GeneChip arrays, but excludes the right to use LabChip technology with respect to products intended primarily to perform nucleic acid separations as a discrete, non-integrated quality control step.


'"/>

Source:Affymetrix


Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
6. Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. Technology for monitoring fetal oxygen during labor offers no apparent benefit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016   Ginkgo Bioworks ... to industrial engineering, was today awarded as one ... selection of the world,s most innovative companies. Ginkgo ... scale for the real world in the nutrition, ... engineers work directly with customers including Fortune 500 ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
Breaking Biology Technology: